FREE SHIPPING ON ORDERS OVER $150

surmount-1 tirzepatide weight loss percent 72 weeks Medscape | Retatrutide, Eli Lilly's first-in-class triple hormone receptor agonist, delivered meaningful at 80 in all doses in the SURMOUNT-1: Adults achieve weight loss

$23.00

Quantity
- +
Description

5 mg weekly (20 mg total per vial)

surmount-1 tirzepatide weight loss percent 72 weeks Medscape | Retatrutide, Eli Lilly's first-in-class triple hormone receptor agonist, delivered meaningful at 80 in all doses in the SURMOUNT-1: Adults achieve weight loss

Meta-analysis data shows retatrutide producing approximately 38% greater weight loss than tirzepatide (16.34 kg versus 11.82 kg)

surmount-1 tirzepatide weight loss percent 72 weeks Medscape | Retatrutide, Eli Lilly's first-in-class triple hormone receptor agonist, delivered meaningful at 80 in all doses in the SURMOUNT-1: Adults achieve weight loss

The first dose will be 2.5 mg for four weeks

surmount-1 tirzepatide weight loss percent 72 weeks Medscape | Retatrutide, Eli Lilly's first-in-class triple hormone receptor agonist, delivered meaningful at 80 in all doses in the SURMOUNT-1: Adults achieve weight loss

Some reported effects remain uncertain in their relationship to tirzepatide

surmount-1 tirzepatide weight loss percent 72 weeks Medscape | Retatrutide, Eli Lilly's first-in-class triple hormone receptor agonist, delivered meaningful at 80 in all doses in the SURMOUNT-1: Adults achieve weight loss

Zepbound is the brand-name FDA-approved product made by Eli Lilly

surmount-1 tirzepatide weight loss percent 72 weeks Medscape | Retatrutide, Eli Lilly's first-in-class triple hormone receptor agonist, delivered meaningful at 80 in all doses in the SURMOUNT-1: Adults achieve weight loss

You may also like

recommand products